GlassScriptPhysician profile
Shari L Skinner
NPI 1043271737
$1,185.15
in general payments reported to CMS, 2019-2025
15 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2021: $35.45 · 2022: $94.53 · 2023: $368 · 2024: $149 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.18 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $187.29 | 2019-2023 | |
| Janssen Biotech, INC. | $185.10 | 2019-2023 | Tremfya |
| Abbvie INC. | $132.30 | 2021-2024 | Rinvoq, Skyrizi |
| Biofrontera INC. | $122.21 | 2025 | |
| Pfizer INC. | $116.68 | 2019-2025 | |
| Celgene Corporation | $91.00 | 2019 | |
| Lilly USA, LLC | $83.75 | 2023-2024 | Ebglyss, Taltz, Olumiant |
| Leo Pharma INC. | $59.27 | 2023-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $56.13 | 2022-2025 | Nemluvio |
| Dermavant Sciences, INC. | $41.74 | 2023 | Vtama |
| Fresenius Kabi USA, LLC | $25.50 | 2024 | Idacio |
| Merck Sharp & Dohme LLC | $24.79 | 2025 | Keytruda |
| Almirall LLC | $23.35 | 2024 | Seysara |
| E.R. Squibb & Sons, L.L.C. | $18.45 | 2024 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $17.59 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shari Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.